Alzheimer’s – Med-stat.info

Chastened after a decisively negative review from outside advisers, the Food and Drug Administration convened a series of internal meetings in March and April where top officials hammered out a …

Health

Q&A: The CEO of the Alzheimer’s Association on the approval of Aduhelm — and why critics should stop dwelling on the decision

16.06.2021

Harry Johns is ready to stop talking about whether or not the Food and Drug Administration should have approved Aduhelm, the divisive new Alzheimer’s treatment that got the green light …

First Opinion

Opinion: If the FDA approves Biogen’s Alzheimer’s treatment, I won’t prescribe it

30.05.2021

Most visits to the memory center where I care for individuals living with Alzheimer’s disease end in disappointment. “Are there any new treatments, Dr. Karlawish?” patients or family members hopefully …

First Opinion

Opinion: Medicare: Cover amyloid PET scans and stop keeping people with dementia in the dark

25.05.2021

One morning in 2012, my wife Geri looked in the mirror and failed to recognize her own face. Our neurologist diagnosed Geri, a former health care executive and nurse, with …

Biotech

FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment

04.11.2020

STAT+ subscribers will have access to all-day coverage of the Friday advisory committee meeting to discuss Biogen’s Alzheimer’s drug, with regular updates on key presentations, interesting arguments, and eventually the …

Tag: Alzheimer’s

Newly disclosed FDA documents reveal agency’s unprecedented path to approving Aduhelm

Q&A: The CEO of the Alzheimer’s Association on the approval of Aduhelm — and why critics should stop dwelling on the decision

Opinion: If the FDA approves Biogen’s Alzheimer’s treatment, I won’t prescribe it

Opinion: Medicare: Cover amyloid PET scans and stop keeping people with dementia in the dark

FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment